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Alpha/beta interferon (IFN) and gamma IFN exert widely overlapping biological effects. Still, mice with
individually inactivated alpha/beta or gamma receptors exhibit variably severely reduced resistance to infec-
tion and altered immune responses. To investigate to what extent the two IFN systems are functionally
redundant, we generated mice with a combined receptor defect (AG129 mice). Like mice with individual
mutations, AG129 mice had no apparent anomalies, confirming that in the mouse the IFN system is not
essential for normal development. These mice showed an additive phenotype with respect to antiviral defense
and exhibited an increased susceptibility to lymphocytic choriomeningitis virus (LCMV) and notably vaccinia
virus infection. Because of unlimited replication and subsequent rapid exhaustion of cytotoxic T lymphocyte
(CTL) precursors, these mice were unable to mount a CTL response to LCMV. CD81-mediated immunopa-
thology was absent in LCMV-infected mice, and virus persisted. Vaccinia virus replicated much faster in
AG129 mice, and a 104-fold lower dose of vaccinia virus was sufficient to prime these mice. With the normal
priming dose of 106 PFU, cytopathic effects and overwhelming infection possibly causing partial exhaustion of
CTL interfered with the anti-vaccinia virus response. Even though global antiviral immunoglobulin G (IgG)
titers were within normal ranges, the IgG subclass distribution was heavily biased toward IgG1.
Interferons (IFNs) are well known for their antiviral effects.
The IFNs can be divided into two classes: alpha, beta, and
omega IFNs (IFN-a, IFN-b, and IFN-v, respectively), which
are encoded by a large family of genes (25), and gamma IFN
(IFN-g), which is structurally unrelated and encoded by a sin-
gle gene (9). IFN-a, IFN-b, and IFN-v presumably bind to a
common receptor (18) composed of several subunits. One re-
ceptor subunit (24), however, seems to be essential for a func-
tional response toward IFN-a, IFN-b, and IFN-v (10, 23).
IFN-g uses a different, unique receptor which is expressed on
many different cell types (1). Both types of IFNs exert pleio-
tropic effects which partly overlap, including stimulation of
major histocompatibility complex antigen expression, inhi-
bition of cell growth including tumor cells, involvement in
hematopoiesis, and regulatory functions in the cellular and
humoral immune response. However, the physiological
significance of IFNs is not completely understood. To study the
in vivo role of IFNs, mice lacking the IFN-a, IFN-b, or IFN-v
receptor (R) or the IFN-g R have been generated by embry-
onic stem cell gene targeting and have been described previ-
ously (10, 17). Mice without a functional IFN-g R (G129 mice)
have been shown to develop normally but have a decreased
resistance to infection with Listeria monocytogenes and vaccinia
virus, despite normal cytotoxic T-lymphocyte (CTL) and
helper responses (10). In contrast, mice lacking a functional
IFN-a/b R (A129 mice) were unable to cope with an array of
viral infections (vaccinia virus, lymphocytic choriomeningitis
virus [LCMV], vesicular stomatitis virus [VSV], and Semliki
Forest virus [17]), whereas the resistance to L. monocytogenes
infection was normal. This shows that the two IFN systems are
functionally nonredundant, at least for some infections. By
crossing A129 mice with G129 mice, double-knockout mice
were generated. These double-knockout mice (AG129) were
healthy by 12 months of age and showed no gross abnormali-
ties in hematological status, in the major lymphocyte subsets,
or in constitutive major histocompatibility complex expression.
We analyzed the effect of absence of both types of IFN Rs on
antiviral defense against LCMV or vaccinia virus. AG129 mice
had the phenotype of A129 mice but exhibited a more pro-
found defect in anti-LCMV and in anti-vaccinia virus response.
MATERIALS AND METHODS
Animals. Mice lacking the IFN-a/b receptor (A129 mice) and those lacking
the IFN-g receptor (G129 mice) have been described previously (10, 17). Mice
lacking both types of receptors (AG129 mice) were obtained by breeding A129
3 G129 mice. A129, G129, and AG129 mice had a pure 129Sv(ev) genetic
background. Control 129Sv(ev) (129), C57BL/6 (B6), and (129 3 B6)F1 mice
were obtained from the Institut fu¨r Zuchthygiene, Tierspital, Zu¨rich, Switzer-
land. Male and female mice used were between 6 and 12 weeks of age. All these
mice are of an H-2b type. For most experiments, 129 mice are used as controls;
however, for some experiments with LCMV B6 mice have been used. B6 and 129
mice showed a difference in anti-vaccinia virus CTL responses, because of a
variation in the H-2Kb molecule and because, in H-2b mice, killing of vaccinia
virus-infected targets is predominantly via H-2Kb. All other responses were
indistinguishable between 129 and B6 mice (data not shown).
Viruses and cell lines. LCMV-WE was originally obtained from F. Lehmann-
Grube, Hamburg, Germany (12), and LCMV-Armstrong (ARM) was obtained
from M. Oldstone, Scripps Clinic and Research Foundation, La Jolla, Calif. (7).
Second-passage virus derived from plaque-purified isolates was propagated on
BHK cells (ARM) or L929 fibroblast cells (WE). Vaccinia virus WR was grown
on BSC40 cells, and the less virulent vaccinia virus strain Lancy was purchased
from the Serum und Impfinstitut, Bern, Switzerland. The recombinant baculo-
viruses expressing the nucleoprotein (NP) of LCMV or of VSV were a generous
gift of D. Bishop, NERC Institute of Virology, Oxford, United Kingdom (3). The
recombinant baculoviruses were derived from nuclear polyhedrosis virus and
were grown at 288C in Spodoptera frugiperda cells in spinner cultures in TC-100
medium (13).
VSV NP-transfected (N1) and mock-transfected (V1) EL4 cells were origi-
nally obtained from L. Lefranc¸ois (20).
Cytotoxicity assays. (i) Primary ex vivo assay. Cytolytic activity of spleen cells
was determined by a 51Cr release assay as described previously (19, 26). Briefly,
mice were injected intravenously (i.v.) 8 days previously with LCMV or 6 days
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previously with vaccinia virus. Doses and virus strains used are indicated in the
results. Spleen cells were suspended at 7 3 106/ml in minimal essential medium
supplemented with 2% fetal calf serum (FCS). MC57G (H-2b) fibroblast target
cells were infected with LCMV (multiplicity of infection 5 0.01) 48 h or with
vaccinia virus (multiplicity of infection 5 5) 3 h before they were used as target.
MC57G cells were labelled with 1 mCi of 51Cr-sodium chromate for 2 h at 378C
(1 3 106 to 10 3 106 cells in 1 ml of minimal essential medium–2% FCS) and
suspended at 105/ml. Threefold dilutions of spleen cells were incubated with 100
ml of targets in 96-well microtiter round-bottom plates for 5 h (LCMV) or 6 h
(vaccinia virus). A total of 70 ml of the supernatant was assayed for released 51Cr.
The percent specific release of 51Cr was calculated as [(experimental release 2
spontaneous release) 3 100/(total release 2 spontaneous release)].
(ii) Secondary CTL assay. Spleen cells (4 3 106/ml) of mice infected with
LCMV (at least 4 weeks ago) or with vaccinia virus (strain Lancy, 6 days ago)
were restimulated in vitro in 1-ml cultures with virus-infected, thioglycolate-
elicited macrophages (2 3 105/ml) in Iscove’s modification of Dulbecco’s mod-
ified medium supplemented with 10% FCS, 1025 M b-mercaptoethanol, and
antibiotics as described previously (19). In the case of vaccinia virus, the cultures
were supplemented with 5% concanavalin A supernatant to support CTL pro-
liferation and activation. After 5 days, cells were resuspended in 0.5 ml of
minimal essential medium–2% FCS and 100 ml was tested in threefold dilutions
on 104 51Cr-labelled targets as described above.
For a virus-independent secondary CTL assay, mice were primed i.v. with 10
mg of Baculo-VSV NP. Two weeks later, spleen cells were restimulated in 1-ml
cultures as described above with irradiated VSV NP-transfected EL4 cells (N1)
or with mock-transfected EL4 cells (V1) as control for 5 days. Undiluted cultures
were assayed for cytotoxicity in a 5-h assay with 51Cr-labelled (see above) V1 and
N1 cells as targets.
Local immunopathology (footpad swelling). Mice were injected in both foot-
pads of the hind legs with 30 ml of virus (indicated in Results) as described
elsewhere (14, 16). Footpad thickness was measured daily from day 5 on with a
spring-loaded caliper. Results are expressed as the percent increase compared
with preinfection values. Data represent the mean of at least four footpads.
Standard deviations were within 10%.
LCMV-specific antibodies. Antibodies were measured with an enzyme-linked
immunosorbent assay (ELISA) as described previously (5). Briefly, ELISA plates
were coated overnight with 10 ng of Baculo-LCMV NP in carbonate buffer (pH
9.6). Sera and peroxidase-labelled anti-mouse immunoglobulin G1 (IgG1),
IgG2a, IgG2b, IgG3, and IgM (PharMingen) were diluted in 1% bovine serum
albumin–phosphate-buffered saline (PBS). Mice were bled 4 weeks after infec-
tion. Results are expressed as the dilution required to obtain an optical density
at 405 nm of 0.5 in a standard assay. All sera were tested in the same assay, and
pooled serum from at least five mice was tested for each experimental condition.
Viral persistence. LCMV persistence was measured in spleens and livers of
mice 20 days after infection with different doses of LCMV-WE or -ARM by a
focus-forming assay on MC57G fibroblasts (4). Each value represents the mean
of at least two mice. Standard deviations were within 15%. Vaccinia virus per-
sistence was measured in lungs of mice 6 days after infection by a standard
plaque assay on BSC40 cells (10).
RESULTS AND DISCUSSION
CTL responses to LCMV. In general, low doses of LCMV
induce a potent CTL response peaking on days 8 to 10; high
doses (.106 PFU) may induce all CTLs, which then are de-
leted (15). Primary ex vivo (Fig. 1A) CTL responses from mice
infected with 100 PFU of LCMV-WE or -ARM were absent in
AG129 mice, whereas splenocytes from similarly primed B6
mice killed LCMV-infected MC57G targets to a considerable
extent. Infection with a high dose of LCMV (106 PFU) also did
not lead to detectable cytotoxic activity in AG129 mice,
whereas in control B6 mice the killing was even higher than
that after infection with 100 PFU (data not shown). The rela-
tively low rate of killing seen in control mice infected with 100
PFU of LCMV-ARM is due to the low replication of this virus
isolate, compared with LCMV-WE, which leads to less exten-
sive CTL priming. Also, secondary responses in AG129 mice
primed with 102, 104, or 106 PFU of LCMV-ARM (Fig. 1B) or
-WE (not shown) were undetectable. Together with virus per-
sistence, this suggested complete exhaustion of antiviral CTL
precursors (CTLp) even by low doses of a relatively slowly
replicating virus (15).
Infection of G129 mice with various doses (102 to 106 PFU)
of LCMV-WE or -ARM induced primary and secondary CTL
responses which were comparable with those in infected con-
trol mice (data not shown and reference 10), whereas infection
of A129 mice with LCMV did not induce any detectable CTL
activity as was the case in AG129 mice (data not shown and
reference 17). Therefore, the IFN-a/b R seems to play a more
important role than the IFN-g R in controlling virus replica-
tion, which in turn regulates the CTL response against LCMV
(15).
CTL response to vaccinia virus. Primary ex vivo CTL re-
sponses after infection with the low-virulence vaccinia virus
strain Lancy were measurable in control 129, A129, and G129
mice after infection with 2 3 106 PFU but not after infection
with a much lower dose (2 3 102 PFU). In contrast, vaccinia
virus-specific cytotoxic activity could also be detected in
AG129 mice after infection with a low dose (2 3 102 PFU) of
vaccinia virus Lancy (Fig. 2A), whereas the response after 2 3
106 PFU of vaccinia virus Lancy was lower compared with 129,
A129, or G129 mice. Even in a secondary CTL assay (Fig. 2B),
no CTLs were detected after priming with 23 102 PFU in 129,
A129, or G129 mice, whereas they were present in AG129
mice. In immunocompetent mice (129) and in mice lacking
only one type of IFN R (A129, G129), a dose of 200 PFU of
vaccinia virus Lancy is apparently too low to prime. Infection
FIG. 1. (A) LCMV-specific CTLs are undetectable in AG129 mice after LCMV infection by a primary ex vivo CTL assay. Mice were infected 8 days previously with
LCMV as indicated in figure. Splenocytes (E) were incubated with 104 LCMV-infected, 51Cr-labelled MC57G target cells (T) for 5 h. Killing is expressed as percent
specific 51Cr release of duplicate cultures. Killing of uninfected MC57G fibroblasts was ,5%. Spontaneous release of infected and uninfected targets was 12 and 11%,
respectively. (B) LCMV-specific CTLs are undetectable in AG129 mice after LCMV infection by a secondary CTL assay. Mice were infected 30 days previously with
LCMV as indicated in figure. Splenocytes (4 3 106/ml) were restimulated with LCMV-infected or control macrophages (0.2 3 106/ml) in 1-ml cultures for 5 days.
Cultures were diluted as indicated and tested for cytotoxicity on 104 LCMV-infected MC57G target cells in a 5-h assay. Killing is expressed as percent specific 51Cr
release of duplicate cultures. Lysis of uninfected MC57G cells was ,5%. Lysis of infected MC57G cells by cells derived from cultures stimulated with uninfected
macrophages was ,10%. Spontaneous release from infected and uninfected targets was 15 and 13%, respectively.
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with 2 3 106 PFU of vaccinia virus Lancy induced specific
CTLs in all four strains tested. However, in all knockout mice
the response was reduced compared with wild-type 129 mice.
This may be explained by the fact that vaccinia virus persists in
all knockout mice (Table 1) as follows: G129 , A129 ,
AG129. Because of this in vivo persistence, replicating vaccinia
virus is transferred to the cultures set up for restimulating
spleen cells in vitro and may interfere with restimulation. Un-
der standard conditions, vaccinia virus used to infect stimulator
cells in secondary cultures is UV inactivated to prevent this
interference. The low primary ex vivo CTL response observed
in AG129 mice after priming with 2 3 106 PFU of vaccinia
virus may be explained by the virus-induced cytopathology,
destroying among other things the integrity of secondary lym-
phoid organs. That this is observed in the double knockouts
only is probably due to a higher replication rate of vaccinia
virus compared with the wild type and single-knockout mice.
CTL response to a nonreplicating agent. To evaluate
whether AG129 mice were able to mount detectable CTL
responses at all, we had to avoid the problem of exhaustion of
CTL by overwhelming virus infection. Therefore, mice were
primed with Baculo-VSV NP that has been shown to prime
CTL responses in vivo in mice and their splenocytes were
restimulated in vitro with VSV NP-transfected (N1) or mock-
transfected (V1, control) EL4 cells. These cultures were sub-
sequently tested for cytolytic activity against N1 and V1 targets.
129 and AG129 mice exhibited killing of N1 to a similar extent
after restimulation with N1 in vitro (Fig. 3), as is true for A129
and G129 mice under similar conditions (data not shown).
Thus, CTL responses per se are not defective in mice lacking
one or both IFN Rs. Killing of N1 cells by V1-restimulated
cultures was below 10% in 13-diluted standard cultures (Fig.
3). Killing of control V1 cells by any of the cultures was always
,20% (data not shown).
Local immunopathology induced by LCMV. Local inflam-
mation resulting from infection into the foot with LCMV is
mediated initially by activated CD81 cells (16). If B6 control
mice were injected with different doses of LCMV-ARM (data
not shown) or -WE (Fig. 4), a dose-dependent footpad swelling
was observed. However, in AG129 mice no footpad swelling
developed after injection of any of the viruses or doses, indi-
cating rapid exhaustion of CTLp by rapidly replicating virus.
Similar data had also been obtained previously with A129 mice
(data not shown and reference 17), whereas G129 mice were
normal in this respect (data not shown and reference 10). It has
been shown (16) that both CD41 and CD81 cells contribute to
local immunopathology. Our data therefore may suggest also a
deleterious effect on CD41 cells in AG129 and A129 mice of
FIG. 2. (A) Vaccinia virus-specific CTLs were present in AG129 mice after
infection with a low and a high dose of vaccinia virus Lancy by a primary ex vivo
CTL assay. Mice were infected 6 days previously with the low-virulence vaccinia
virus strain Lancy as indicated in figure. Splenocytes (E) were incubated with 104
vaccinia virus-infected, 51Cr-labelled MC57G target cells (T) for 6 h. Killing is
expressed as percent specific 51Cr release of duplicate cultures. Killing of unin-
fected MC57G targets was,5%. Spontaneous release of infected and uninfected
targets was 11 and 19%, respectively. (B) Vaccinia virus-specific CTLs are
present in AG129 mice after infection with vaccinia virus Lancy by a secondary
CTL assay. Mice were infected 6 days previously with vaccinia virus as indicated
in the figure. Splenocytes (4 3 106/ml) were restimulated with vaccinia virus-
infected (UV-inactivated) macrophages (0.23 106/ml) for 5 days in the presence
of 5% concanavalin A supernatant. Cultures were diluted as indicated and tested
for cytotoxicity on 104 vaccinia virus-infected MC57G targets in a 6-h assay.
Killing is expressed as percent specific 51Cr release from duplicate cultures. Lysis
of uninfected MC57G cells was always,3%. Lysis of infected MC57G targets by
cells derived from cultures stimulated with uninfected macrophages was ,10%.
Spontaneous release from uninfected and infected targets was 16 and 18%,
respectively.
FIG. 3. Normal levels of CTLs are present in AG129 mice after priming with
a nonreplicating agent. Mice were primed i.v. with 10 mg of Baculo-VSV NP.
Two weeks later, splenocytes were restimulated (4 3 106/ml) with VSV NP-
transfected (N1) or mock-transfected (V1) EL4 cells (0.2 3 106/ml) in 1-ml
cultures for 5 days. Cultures were tested for cytotoxic activity on 104 51Cr-
labelled N1 targets in a 5-h assay. Killing is expressed as percent specific 51Cr
release of duplicate cultures. Killing of V1 by N1- or V1-stimulated cultures was
,20% (not shown); killing of N1 by V1-stimulated cultures was ,5%. Sponta-
neous release of V1 and N1 targets was 17 and 18%, respectively. (AG)1293 V1
and (AG)129 3 N1, spleen cells from (AG)129 mice restimulated with V1 or N1
in vitro.
TABLE 1. Vaccinia virus persistence in wild-type
and IFN R2/2 micea
Inoculum
PFU/lung
129 A129 G129 AG129
2 3 102 ,102 1.0 3 105 ,102 9.0 3 105
2 3 106 ,102 5.5 3 105 1.0 3 103 2.0 3 106
aMice were infected with indicated doses of vaccinia virus Lancy. Indicated
are the number of PFU per lung 6 days after infection. The values represent the
mean of two individual mice. Standard deviation was ,15%. 129, wild type;
A129, IFN-a/b R2/2; G129, IFN-g R2/2; AG129, IFN-a/b and IFN-g R2/2.
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LCMV infection. However, two arguments are against this
interpretation. First, exhausting conditions in immunocompe-
tent mice (.106 PFU of LCMV-DOCILE in B6 mice) do not
affect the function of LCMV-specific CD41 cells as measured
by proliferation, B-cell help, and lymphokine production (24a),
and second, perforin knockout mice which have a normal
CD41 compartment do not display footpad swelling after local
infection with LCMV. The apparent CD8 dependence of foot-
pad swelling may be explained by the fact that viral persistence
at a high level prevents immunopathology by exhausting CD81
T cells. This reduces freeing of cell internal viral antigen and
therefore also the class II presentation of viral epitopes to
CD41 cells.
Viral persistence. Viral persistence was measured in spleen
and liver of mice infected 20 days previously with different
doses of LCMV-ARM or -WE (Table 2). All control B6 mice
had cleared the virus below detection level (titers of ,100
PFU/g of tissue), whereas AG129 mice were unable to clear
the virus. The rapidly replicating virus (LCMV-WE) led to
higher virus titers in spleen compared with the somewhat more
slowly replicating strain (LCMV-ARM). It has been shown
(10) that G129 mice eliminated LCMV-WE from most tissues,
whereas A129 mice did not. Persistence of the low-virulence
strain vaccinia virus Lancy that normally does not replicate
measurably in C57BL/6 mice was measured in lungs of mice 6
days after infection in mutant mice (Table 1): wild-type 129
and G129 mice cleared the virus after infection with 2 3 102
PFU, whereas AG129 and A129 were not able to cope with this
low dose. Infection with 2 3 106 PFU invariably led to persis-
tence in all knockout mice. This is in agreement with our
previous observations (10, 17) that G129 mice were able to
cope with infection with the virulent strain vaccinia virus WR,
whereas A129 mice succumbed to it. AG129 mice even died
(.14 days) after infection with a high dose of vaccinia virus
Lancy.
LCMV NP-specific antibodies. Antibodies were measured in
sera from mice infected i.v. 4 weeks earlier with 100 PFU of
LCMV-WE. No differences among 129, A129, G129, and
AG129 mice with respect to total IgG anti-LCMV NP could be
detected (not shown). When IgG isotypes were analyzed, how-
ever, clear differences were found (Table 3): compared with
control 129 mice, both G129 and AG129 mice had significantly
more virus-specific IgG1, whereas IgG2a levels were compa-
rable in 129 and A129 mice and somewhat reduced in G129
mice but undetectable in AG129 mice. IgG3 was low in all four
strains, and IgG2b was significantly enhanced in G129 mice.
This suggests a role for IFN-g in the downregulation of virus-
specific IgG1 and IgG2b responses, whereas the lack of IFN-
a/b apparently does not influence the subclass pattern signif-
icantly. However, if both types of IFN were lacking, the IgG2a
and IgG2b responses were reduced to very low levels. Al-
though IFN-g has been implicated in promoting isotype switch
to IgG2a (21), the absence of IFN-g resulted only in a reduc-
tion, not the complete absence, of IgG2a (this study and ref-
erence 10). IFN-a/b has also been shown to enhance IgG2a
secretion (8). It is interesting that the IgG2a production is
abolished only when both IFN systems are inactive, suggesting
a synergistic action for IFN-g and IFN-a/b in promoting IgG2a
production. In contrast, the enhanced IgG2b production in the
absence of IFN-g seems to be reversed if the receptor for
IFN-a/b is absent.
Taken together, AG129 (IFN-a/b and IFN-g R2/2) mice
display generally an additive phenotype of A129 (IFN-a/b
R2/2) and G129 (IFN-g R2/2) with respect to antiviral de-
fense. As in A129 mice, CTLs and CTLp against LCMV are
readily deleted in AG129 mice because of overwhelming virus
replication and exhaustive CTL activation (14, 15). This results
in a lack of virus-specific CTLp leading to lifelong viral persis-
tence of LCMV. In vaccinia virus infection, both IFN Rs seem
to be additive: IFN-a/b R is the most crucial but the IFN-g R
certainly contributes to anti-vaccinia virus control. In some
viral infections, studied previously (17), the absence of a func-
tional IFN-a/b and IFN-v system proved to have a major
FIG. 4. Local, LCMV-induced, CD8-mediated immunopathology is absent
in AG129 mice. Mice were injected in the footpad of both hind legs with LCMV
as indicated in figure. Footpad swelling was measured daily from day 5 on.
Results are expressed as fold increase compared with noninfected feet. Data
represent the mean of four footpads; standard deviation was within 10%.
TABLE 2. LCMV persistence in IFN-a/b and IFN-g R2/2
(AG129) and control B6 micea
LCMV strain (PFU)
PFU/g (104)
Spleen Liver
B6 AG129 B6 AG129
WE (102) ,102 9.8 3 104 ,102 1.8 3 104
WE (104) ,102 2.9 3 105 ,102 8.0 3 103
WE (106) ,102 3.3 3 105 ,102 2.7 3 104
ARM (102) ,102 5.8 3 104 ,102 1.7 3 104
ARM (104) ,102 1.0 3 105 ,102 2.1 3 104
ARM (106) ,102 5.0 3 103 ,102 5.0 3 103
aMice were infected with indicated doses of LCMV-ARM or -WE, and organs
were ground and plaqued on MC57G fibroblasts 4 weeks later. Indicated are the
number of PFU per gram of tissue. The values represent the mean of two
individual mice. Standard deviation was always ,15%.
TABLE 3. LCMV NP-specific antibodies: dependence of IgG
isotype pattern on the presence of IFN Rsa
Ig 129 A129 G129 AG129
IgG1 800 1,600 51,200 51,200
IgG2a 6,400 6,400 3,200 ,50
IgG2b 800 1,600 12,800 50
IgG3 ,50 ,50 ,50 ,50
a Results are given as the dilution needed to yield a signal of 0.5 in a standard
ELISA. Results are obtained with pools of five serum samples per mouse strain.
Mice were bled 4 weeks after infection with 200 PFU of LCMV-WE. 129,
control; A129, IFN-a/b R2/2; G129, IFN-g R2/2; AG129, IFN-a/b and IFN-g
R2/2.
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impact on antiviral defense, whereas no effect was observed
when the IFN-g system was deficient. The present findings
illustrate that in some viral infections the two systems act
cooperatively. This may particularly be relevant in cases in
which viruses evolved mechanisms to escape IFN-a, IFN-b,
and IFN-v action (2, 6, 11, 22). Recent observations with
Theiler’s virus (7a) also illustrate the cooperation of the two
systems and support the notion that the IFN-a, IFN-b, and
IFN-v system mainly inhibits early spread from the primary
site of infection, whereas the IFN-g system may play a more
important role in latter stages of viral infection, notably in
controlling persistence. Because of the virtual absence of in-
nate defense which contributes to the subsequent exhaustion
of acquired immune responses, mice with the combined defi-
ciency of both IFN systems may provide unique conditions to
isolate infectious agents that normally cannot escape immune
surveillance.
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